Clinical study to evaluate the efficacy and safety of an oral care product on oral malodour reduction and its causative microflora in healthy adult subjects

Start Date12 Jul 2021

Sponsor / Collaborator

Dabur India Ltd.

100 Clinical Results associated with Argidene

100 Translational Medicine associated with Argidene

100 Patents (Medical) associated with Argidene

2,675

Literatures (Medical) associated with Argidene

01 May 2025·Journal of Colloid and Interface Science

Electrosprayed core–shell microspheres co-deliver fibronectin and resveratrol for combined treatment of acute lung injury

Article

Author: Sun, Huxiao ; Ma, Jing ; Zhang, Guixiang ; Shi, Xiangyang ; Shen, Mingwu ; Huang, Yifan ; Zhan, Mengsi ; Zhang, Caiyun

The facile development of advanced formulations capable of scavenging excess reactive oxygen species (ROS) and sustainably inhibiting inflammatory cytokine secretion is imminent for effective treatment of acute lung injury (ALI), but still remains a great challenge. This study presents an innovative core-shell carrier system via electrospray technology, characterized by a shell of poly(lactic acid-co-glycolic acid) (PLGA) and a core consisting of polycaprolactone-polyethylene glycol (PCL-PEG) micelles encapsulating resveratrol (Res), and surface modified with fibronectin (FN). The created drug-loaded core-shell microspheres (for short, RPG@FN) with a size of 1.30 μm, are stable under physiological conditions and specifically target macrophages through the Arg-Gly-Asp peptide sequence of FN. We show that the RPG@FN microspheres can synergistically reduce inflammatory responses through ROS scavenging and macrophage M2 polarization, thus facilitating mitochondrial homeostasis restoration and modulating NF-κB and PI3K/Akt pathways by virtue of the integrated antioxidant and anti-inflammatory properties of FN and Res. In an ALI mouse model, the developed RPG@FN significantly alleviates pulmonary edema and inflammatory cell infiltration, while repairing the inflammatory lung injury. This innovative RPG@FN system fully capitalizes on the therapeutic benefits of Res and FN with improved bioavailability, thus offering a promising option for effective ALI treatment.

01 Apr 2025·Biomaterials

Synthetic hydrogel substrate for human induced pluripotent stem cell definitive endoderm differentiation

Article

Author: Marquez, Elijah N. ; Helmrath, Michael ; Mora-Boza, Ana ; García, Andrés J ; Ziegelski, Morgan ; García, Andrés J. ; Mulero-Russe, Adriana ; Marquez, Elijah N

Human induced pluripotent stem cells (hiPSCs) can give rise to multiple lineages derived from three germ layers, endoderm, mesoderm and ectoderm. Definitive endoderm (DE) cell types and tissues have great potential for regenerative medicine applications. Current hiPSC differentiation protocols focus on the addition of soluble factors; however, extracellular matrix properties are known to also play a role in dictating cell fate. Matrigel™ is the gold standard for DE differentiation, but this xenogeneic, poorly defined basement membrane extract limits the clinical translatability of DE-derived tissues. Here we present a fully defined PEG-based hydrogel substrate to support hiPSC-derived DE differentiation. We screened hydrogel formulations presenting different adhesive peptides and matrix stiffness. Our results demonstrate that presenting a short peptide, cyclic RGD, on the engineered PEG hydrogel supports the transition from undifferentiated hiPSCs to DE using a serum-free, commercially available kit. We show that increasing substrate stiffness (G' = 1.0-4.0 kPa) results in an increased linear response in DE differentiation efficiency. We also include a temporal analysis of the expression of integrin and syndecan receptors as the hiPSCs undergo specification towards DE lineage. Finally, we show that focal adhesion kinase activity regulates hiPSC growth and DE differentiation efficiency. Overall, we present a fully defined matrix as a synthetic alternative for Matrigel™ supporting DE differentiation.

01 Apr 2025·Advanced Materials

Photo‐Responsive H₂S Composite System Regulates the Nerve Regeneration Microenvironment Through Multiple Pathways

Article

Author: Li, Zhiqiang ; Liang, Xinyue ; Yu, Aixi ; Liu, Kun ; Huo, Yuanfang ; Tan, Xinyi ; Yao, Yawei ; Zhang, Hao ; Dai, Honglian ; Dong, Xianzhen ; Pang, Zixuan ; Yang, Junwei

AbstractAfter injury, the imbalance of the regeneration microenvironment caused by inflammation, oxidative stress, insufficient neurovascularization, and inadequate energy supply affects nerve regeneration. Drug‐delivery nerve conduits play a role in repairing the regenerative microenvironment. However, traditional drugs often fail to cross the blood‐nerve barrier and lack multifunctionality, limiting the effectiveness of conduit therapy. Therefore, it is necessary to construct a multifunctional conduit that regulate the regeneration microenvironment timely and effectively. Herein, a photo‐responsive hydrogen sulfide (H2S) composite nerve conduit, artificially controlled H2S release, is developed. A new structure of zinc‐citric acid organic metal framework (Zn‐CA MOFs) is utilized to improve its drug loading rate, achieving the joint regulation of the nerve regeneration microenvironment by H2S and Zn2+. In addition, RGD modification of polyester amide (P(CL‐MMD‐MAC)‐RGD)) combined with aligned structure is used to improve the performance of the conduit. Relevant results demonstrate that H2S and Zn2+ can regulate inflammatory response and oxidative stress and promote mitochondrial function recovery and angiogenesis. Furthermore, the aligned structure can promote cell adhesion and guide cell directed migration. Overall, this study provides a method of combining gas neurotransmitters with ions to improve the nerve regeneration microenvironment, accelerate nerve regeneration, and restore motor function.

100 Deals associated with Argidene

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Foot	NDA/BLA	United States	Telios Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Argidene

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation